Drugs / CNP-106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06106672 | May 2024 → Jun 2026 overdue | AChR+ myasthenia gravis, generalized myasthenia gravis, muscle-specific tyrosine kinase-associated myasthenia gravis | COUR Pharmaceutical Development Company, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNP-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06106672 ↗ |
| Modality | Peptide | “CNP-106 is comprised of an antigenic AChR Peptide Pool” NCT06106672 ↗ |
| Route | Intravenous | “200 mL intravenous infusion on Day 1 and Day 8: CNP-106” NCT06106672 ↗ |